SS Innovations International (NASDAQ: SSII) has announced record financial results for the second quarter of 2026, with revenue reaching $13.9 million, a 39.4% increase from $10 million in the same period last year. The growth is attributed to a 30.4% rise in installations of its SSi Mantra surgical robotic system, which totaled 30 during the quarter. The company also reported a gross profit of $7.1 million, reflecting a 20% increase, and a gross margin of 50.9%. Despite a net loss of $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million in the prior year, the company's first-half revenue surged 65.6% to $25 million, with installations up 47.4% to 56.
The company's financial health appears robust, with $13.6 million in cash and cash equivalents and no long-term debt as of June 30. The cumulative installed base of SSi Mantra systems has reached 224 across 12 countries, highlighting the global adoption of the technology. Notably, the company has performed 12,272 cumulative procedures using the SSi Mantra, including 175 telesurgeries. A landmark achievement was a robotic telesurgery that spanned more than 13,600 miles between Colombia and India, underscoring the potential of remote surgical capabilities to transform healthcare delivery worldwide.
Looking ahead, SS Innovations anticipates that the U.S. Food and Drug Administration (FDA) will complete its review of the company's 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027. Additionally, the company believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are critical for expanding access to the SSi Mantra in major markets, potentially increasing competition and lowering costs in robotic surgery.
The implications of these developments are significant for the healthcare industry. Robotic surgery offers benefits such as reduced recovery times and increased precision, but its adoption has been limited by high costs and complexity. SS Innovations aims to make robotic surgery more affordable and accessible globally, which could democratize advanced surgical care. The company's focus on cost-effective solutions and its success in telesurgery could also pave the way for remote surgical consultations and procedures, particularly in underserved regions.
As the company continues to grow and meet regulatory requirements, stakeholders will be watching closely. The record revenue and expanding installed base demonstrate strong market demand, and the anticipated FDA and CE approvals could further accelerate adoption. For more information, visit the full press release at https://ibn.fm/nTMso and the company's newsroom at https://ibn.fm/SSII.
